Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 9.04
CRDC's Cash to Debt is ranked higher than
81% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.05 vs. CRDC: 9.04 )
CRDC' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 9.04

Equity to Asset 0.77
CRDC's Equity to Asset is ranked higher than
87% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.56 vs. CRDC: 0.77 )
CRDC' s 10-Year Equity to Asset Range
Min: -5.64   Max: 0.86
Current: 0.77

-5.64
0.86
F-Score: 4
Z-Score: -5.81
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -590.56
CRDC's Operating margin (%) is ranked lower than
55% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.05 vs. CRDC: -590.56 )
CRDC' s 10-Year Operating margin (%) Range
Min: -1065.07   Max: -26.6
Current: -590.56

-1065.07
-26.6
Net-margin (%) -603.71
CRDC's Net-margin (%) is ranked lower than
55% of the 314 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.31 vs. CRDC: -603.71 )
CRDC' s 10-Year Net-margin (%) Range
Min: -1281.1   Max: -26.56
Current: -603.71

-1281.1
-26.56
ROE (%) -76.18
CRDC's ROE (%) is ranked lower than
52% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.20 vs. CRDC: -76.18 )
CRDC' s 10-Year ROE (%) Range
Min: -171.5   Max: -45.86
Current: -76.18

-171.5
-45.86
ROA (%) -59.13
CRDC's ROA (%) is ranked lower than
54% of the 318 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. CRDC: -59.13 )
CRDC' s 10-Year ROA (%) Range
Min: -108.53   Max: -33.08
Current: -59.13

-108.53
-33.08
ROC (Joel Greenblatt) (%) -867.43
CRDC's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.46 vs. CRDC: -867.43 )
CRDC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1119.89   Max: -343.27
Current: -867.43

-1119.89
-343.27
Revenue Growth (3Y)(%) -51.30
CRDC's Revenue Growth (3Y)(%) is ranked lower than
53% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. CRDC: -51.30 )
CRDC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 13.6
Current: -51.3

0
13.6
EBITDA Growth (3Y)(%) 33.20
CRDC's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. CRDC: 33.20 )
CRDC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -54.9   Max: 33.2
Current: 33.2

-54.9
33.2
EPS Growth (3Y)(%) 31.70
CRDC's EPS Growth (3Y)(%) is ranked higher than
91% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. CRDC: 31.70 )
CRDC' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.5   Max: 31.7
Current: 31.7

-51.5
31.7
» CRDC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CRDC Guru Trades in Q2 2014

PRIMECAP Management 5,842,700 sh (+124.75%)
Jim Simons Sold Out
Chuck Royce 114,486 sh (-32.50%)
» More
Q3 2014

CRDC Guru Trades in Q3 2014

PRIMECAP Management 5,864,500 sh (+0.37%)
Chuck Royce 54,486 sh (-52.41%)
» More
Q4 2014

CRDC Guru Trades in Q4 2014

PRIMECAP Management 6,013,500 sh (+2.54%)
Chuck Royce Sold Out
» More
Q1 2015

CRDC Guru Trades in Q1 2015

PRIMECAP Management 6,013,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRDC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.78
CRDC's P/B is ranked higher than
63% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.19 vs. CRDC: 4.78 )
CRDC' s 10-Year P/B Range
Min: 1.26   Max: 15.73
Current: 4.78

1.26
15.73
P/S 10.75
CRDC's P/S is ranked lower than
58% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. CRDC: 10.75 )
CRDC' s 10-Year P/S Range
Min: 1.54   Max: 35.68
Current: 10.75

1.54
35.68
Current Ratio 10.02
CRDC's Current Ratio is ranked higher than
98% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.58 vs. CRDC: 10.02 )
CRDC' s 10-Year Current Ratio Range
Min: 1.7   Max: 21.42
Current: 10.02

1.7
21.42
Quick Ratio 9.47
CRDC's Quick Ratio is ranked higher than
98% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. CRDC: 9.47 )
CRDC' s 10-Year Quick Ratio Range
Min: 1.26   Max: 20.95
Current: 9.47

1.26
20.95
Days Inventory 100.16
CRDC's Days Inventory is ranked higher than
83% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 135.02 vs. CRDC: 100.16 )
CRDC' s 10-Year Days Inventory Range
Min: 40.75   Max: 149.78
Current: 100.16

40.75
149.78
Days Sales Outstanding 44.06
CRDC's Days Sales Outstanding is ranked higher than
92% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 71.94 vs. CRDC: 44.06 )
CRDC' s 10-Year Days Sales Outstanding Range
Min: 9.01   Max: 82.52
Current: 44.06

9.01
82.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.27
CRDC's Price/Net Cash is ranked higher than
99% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. CRDC: 2.27 )
CRDC' s 10-Year Price/Net Cash Range
Min: 2.52   Max: 107.5
Current: 2.27

2.52
107.5
Price/Net Current Asset Value 14.33
CRDC's Price/Net Current Asset Value is ranked higher than
82% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.00 vs. CRDC: 14.33 )
CRDC' s 10-Year Price/Net Current Asset Value Range
Min: 1.99   Max: 48.75
Current: 14.33

1.99
48.75
Price/Tangible Book 4.78
CRDC's Price/Tangible Book is ranked higher than
72% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.00 vs. CRDC: 4.78 )
CRDC' s 10-Year Price/Tangible Book Range
Min: 1.68   Max: 14.33
Current: 4.78

1.68
14.33
Price/Median PS Value 0.78
CRDC's Price/Median PS Value is ranked higher than
92% of the 345 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.38 vs. CRDC: 0.78 )
CRDC' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.94
Current: 0.78

0.16
1.94
Earnings Yield (Greenblatt) -58.80
CRDC's Earnings Yield (Greenblatt) is ranked lower than
57% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.60 vs. CRDC: -58.80 )
CRDC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -82.8   Max: 0
Current: -58.8

-82.8
0

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 3 3 7 19
EPS($) -0.22 -0.21 -0.19 -0.13
EPS without NRI($) -0.22 -0.21 -0.19 -0.13

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:C5V.Germany,
Cardica Inc was incorporated in Delaware in October 1997 as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. The Company designs, manufactures and markets proprietary automated anastomotic systems used by cardiac surgeons to perform coronary bypass surgery. It is developing the MicroCutter XCHANGE 30, a cartridge-based microcutter device with a 5-millimeter shaft diameter, designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Company's C-Port Distal Anastomosis Systems, or C-Port systems, are sold in the United States and Europe. The C-Port systems are used to perform a distal anastomosis, which is the connection between a bypass graft vessel and the target coronary artery. It currently markets three proprietary products to perform anastomoses, the C-Port xA system, the C-Port Flex A system and the PAS-Port system. The C-Port systems automate a distal anastomosis between the graft vessel and target artery. The C-Port xA system was developed to use veins and arteries as the bypass graft vessel and received 510(k) clearance in November 2006. A new generation of the C-Port xA system, the C-Port Flex A system, designed to further enable minimally invasive CABG surgery, received 510(k) clearance in March 2007. The PAS-Port system automates the performance of a proximal anastomosis between a graft vessel, typically a saphenous vein, and the aorta. The PAS-Port system received 510(k) clearance in September 2008 following successful completion of a prospective, international, randomized study. The Company's main competitors include Ethicon Endo-Surgery, part of Johnson & Johnson, and Covidien. The FDA and other regulatory bodies extensively regulate the research, development, manufacture, labeling, distribution and marketing of its products.
» More Articles for CRDC

Headlines

Articles On GuruFocus.com
comment on CRDC Mar 23 2013 
CARDICA, INC. Reports Operating Results (10-Q) Feb 11 2011 
CARDICA, INC. Reports Operating Results (10-Q) Nov 15 2010 
CARDICA, INC. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buy Highlight: CARDICA, NewBridge Bancorp, WESCO International, PrivateBancorp Inc., Syno Nov 07 2009 
CARDICA, INC. Reports Operating Results (10-Q) Nov 06 2009 
CARDICA, INC. (CRDC) CFO Robert Y Iv Newell buys 16,000 Shares Nov 04 2009 
Weekly CFO Buy Highlights: Cardica, Inc. (CRDC), American International Industries Inc (AMIN) Oct 10 2009 
CARDICA, INC. (CRDC) CEO Bernard A Hausen buys 19,960 Shares Oct 02 2009 
CARDICA, INC. (CRDC) CFO Robert Y Iv Newell buys 11,976 Shares Oct 02 2009 

More From Other Websites
CARDICA INC Financials May 22 2015
Cardica Announces New Employment Inducement Grant May 21 2015
CARDICA INC Files SEC form 8-K, Change in Directors or Principal Officers May 21 2015
Cardica Announces New Employment Inducement Grant May 21 2015
10-Q for Cardica, Inc. May 14 2015
5 Stocks Under $10 Set to Soar May 14 2015
CARDICA INC Files SEC form 10-Q, Quarterly Report May 12 2015
Cardica Announces Fiscal 2015 Third Quarter Financial Results May 06 2015
Cardica Inc Earnings Call scheduled for 4:30 pm ET today May 06 2015
CARDICA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 06 2015
Cardica Announces Fiscal 2015 Third Quarter Financial Results May 06 2015
Q3 2015 Cardica Inc Earnings Release - After Market Close May 06 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
Cardica To Announce Fiscal 2015 Third Quarter Financial Results On Wednesday, May 6, 2015 Apr 28 2015
CARDICA INC Files SEC form 8-K, Other Events Apr 23 2015
Baxter Partners Aguettant for Trace Elements in PN Therapy - Analyst Blog Apr 06 2015
Baxter's HOMECHOICE CLARIA APD System Gets CE Mark - Analyst Blog Apr 02 2015
3 Stocks Under $10 to Trade for Big Breakouts Mar 31 2015
Cardica, Inc. Business Update Call scheduled for 8:30 am ET today Mar 26 2015
CARDICA INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in... Mar 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK